Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin plus veliparib for inoperable pancreatic adenocarcinoma with ATM mutation
2014-003785-24Phase 2Completed
- Sponsor
- Uzsoki Utcai Kórház
- Start
- Sep 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of veliparib and carboplatin in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Uzsoki Utcai Kórház. Primary endpoint: Disease progression or conversion to resectable tumor. Started Sep 2014; status: completed.
02
Drugs
veliparibcarboplatin
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2014-003785-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003785-24.